Trial-Results center  
Clinical trial results database in 100 Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - antioxydants - secondary prevention

cardiovascular prevention - antioxydants - all type of patients


Related trials

PHS II vitamin C, 2008 - vitamin C vs placebo

POPADAD (antioxydant), 2008 - combination vs placebo

ARISE, 2008 - succinobucol vs placebo

PHS II vitamin E, 2008 - vitamin E vs placebo

WACS beta-caroten, 2007 - beta carotene vs placebo

WACS vitamin E, 2007 - vitamin E vs placebo

WACS vitamin C, 2007 - vitamin C vs placebo

WHS vitamin E, 2005 - vitamin E vs placebo

SUVIMAX, 2005 - combination vs placebo

HOPE renal insufficiency subgroup, 2004 - vitamin E vs placebo

PHS II beta carotene, 2003 - combination vs placebo

Tepel, 2003 - acetylcysteine vs placebo

WAVE (Waters), 2002 - combination vs placebo

HPS antioxidant, 2002 - combination vs placebo

HATS, 2001 - combination vs placebo

PPP, 2001 - vitamin E vs control

AREDS, 2001 - vitamin E vs placebo

HOPE, 2000 - vitamin E vs placebo

ASAP, 2000 - vitamin E vs placebo

SPACE, 2000 - vitamin E vs placebo

WHS beta carotene, 1999 - beta carotene vs placebo

GISSI, 1999 - vitamin E vs control

NSCP (Green) beta carotene, 1999 - beta carotene vs placebo

ATBC 2nd prev subgroup (vitamin E), 1998 - vitamin E vs placebo

ATBC 2nd prev subgroup (b carotene), 1998 - beta carotene vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of antioxydants
  • All clinical trials of combination
  •  

    MVP study, 1997

    download pdf: combination | antioxydants for cardiovascular prevention

    Treatments

    Studied treatment multivitamins (30,000 IU of beta carotene, 500 mg of vitamin C, and 700 IU of vitamin E) for four weeks before and six months after angioplasty
    Control treatment placebo
    Remarks factorial design: probucol and multivitamins

    Patients

    Patients patient undergoing angioplasty
    Inclusion criteria scheduled to undergo standard balloon angioplasty on at least one native coronary artery and had at least one target lesion with stenosis of 50 percent or more of the luminal diameter as measured by calipers on the angiogram
    Exclusion criteria unable to participate in the pretreatment evaluation or unable to return for follow-up; myocardial infarction within the previous seven days; scheduled to undergo stenting or atherectomy; prior angioplasty for another lesion in the preceding six months; treatement for a restenotic lesion; angioplasty of a bypass graft or of a bypassed native vessel with a patent graft

    Method and design

    Randomized effectives 158 / 159 (studied vs. control)
    Design Factorial plan
    Blinding double-blind
    Follow-up duration 6 montsh
    Premature discontinuation Premature discontinuation for efficacy
    Number of centre single center
    Geographic area Canada
    Hypothesis Superiority
    Primary endpoint extent of restenosis

    Remarks / Comments

    premature stopping for efficacy of probucol



    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Coronary event

    2 / 158
    3 / 159
    classic 0,67 [0,11;3,96]

    All cause death

    1 / 158
    1 / 159
    classic 1,01 [0,06;15,95]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    Coronary event 2 / 158 (1,3%) 3 / 159 (1,9%) 0,67 [0,11;3,96] MI  13137
    All cause death 1 / 158 (0,6%) 1 / 159 (0,6%) 1,01 [0,06;15,95]   13137
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 13137: Tardif JC, Cöté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise PProbucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.N Engl J Med 1997;337:365-72
  • 0:

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Coronary event 1,27% 1,89% -6,2‰
    All cause death 6,33‰ 6,29‰ 0,0‰

    Meta-analysis of all similar trials:

    antioxydants in cardiovascular prevention for secondary prevention

    antioxydants in cardiovascular prevention for all type of patients



    Reference(s)

    Trials register # NA
    • Tardif JC, Cöté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.. N Engl J Med 1997;337:365-72
      Pubmed | Hubmed | Fulltext

    (c) 2004-2012 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100